Here's some more news on Caduceon:
IDS announces key management appointments at Caduceon
9:41 EST Friday, March 10, 2000
Biotech and manufacturing leaders guiding Caduceon to the frontier of
diagnostic medicine
TORONTO, March 10 /CNW/ - Intelligent Detection Systems Inc. (TSE: ISD) announced today the appointments of
Graham Strachan, Dr. Lawrence V. Haley, Adrian Beale and Dr. Ignace Krizancic to key management positions at
Caduceon, its medical diagnostic technology company. Using IDS's proprietary automated chemical analysis technology,
Caduceon is developing medical diagnostic applications that hold the promise of early detection of disease and dysfunction
using breath samples. Other applications of this rapid and noninvasive chemical analysis technology include well being and
lifestyle monitoring, and workplace safety.
Graham Strachan has been confirmed in his position of Executive Chair. Since October 1999 Mr. Strachan has held this
position. His re-appointment reflects the success Mr. Strachan has achieved in developing a strong business plan and
attracting key management to realize his vision. At Caduceon Mr. Strachan is continuing to build upon his strong reputation
as a leader in Canada's biotechnology sector. Prior to joining Caduceon, Mr. Strachan was President and CEO of Allelix
Biopharmaceuticals Inc., one of Canada's leading developers of innovative pharmaceutical products. Among Mr.
Strachan's many accomplishments at Allelix was the successful raising of new capital and leading the merger with NPS,
resulting in the creation of a company with a market capitalization of more than $1 billion.
Dr. Lawrence Haley has been appointed to the position of Chief Technology Officer. Dr. Haley was instrumental in the
development of IDS's patented gas chromatography/ion mobility spectrometry (GC/IMS) technology for more than 10
years. The original application for this technology has been in the field of trace detection of explosives and drugs. This
application provides the competitive advantage that makes IDS's Analytical and Security division a market leader in
explosives and drug detection around the world. At Caduceon, Dr. Haley is applying his unparalleled understanding of the
capabilities of the GC/IMS technology to the pursuit of medical diagnostic solutions.
Adrian Beale has been appointed to the position of President at Caduceon. Mr. Beale brings more than 20 years of senior
manufacturing experience to his new role. Before joining Caduceon, Mr. Beale held senior management positions with
IDS, Scintrex Ltd., Novatel and Amdahl. His operational experience ranges from start up companies to large multinational
corporations. At Caduceon Mr. Beale is focusing on the adaptation of Caduceon's proven GC/IMS technology to address
medical diagnostic applications.
Dr. Ignace Krizancic has been appointed Vice President, Marketing at Caduceon. Dr. Krizancic has gained extensive
business experience in the development, organization and financing of technology intensive enterprises including
biotechnology. He has a comprehensive background that ranges from the management of a $100 million dollar venture
capital fund to strategic planning for organizations such as the Canadian Space Agency, Gulf Canada, the Royal Bank,
Allied Signal, the Government of Canada and the Department of National Defense. Dr. Krizancic brings his considerable
experience and abilities to the marketing and strategic development of Caduceon's medical diagnostic technology.
About Caduceon
Caduceon Inc. is headed by the Executive Chair, Graham Strachan, who has an extensive network of bio/pharmaceutical
contacts. He is the former President and CEO of Allelix Biopharmaceuticals Inc. and member of several key bioscience
advisory groups. The company is adapting the GC/IMS process to detect the more than 400 chemical compounds found
in the human breath. These compounds are indicators of our state of health; many of these function as bio-markers of
significant disease and dysfunction, including oxidative stress. The market for a sophisticated, noninvasive, sensitive,
cost-effective device for use at the bedside is large and growing.
About IDS
IDS is an innovative developer, manufacturer and marketer of proprietary sensory technology and communication systems.
The company operates through eight business units: Analytical & Security products and solutions, IDS Power Control
Systems, Scintrex Earth Science Instrumentation, Survey & Exploration Technology Services, IEC (Integration,
Engineering and Consulting), ChemiCorp International and Caduceon Inc. Its more than 70 products range from drug and
explosives detectors to nuclear safety control instruments, mineral and petroleum exploration instrumentation and services,
and developing technologies for industrial process control and point-of-care health analysis. IDS's business-to-business
e-commerce company, GeoCommerce Inc., provides centralized online trading and information marketplaces for the
global mining, exploration, and geophysics communities through: www.MineOnline.com and www.GeophysicsOnline.com.
IDS operates worldwide in Canada, the US, France, UK, Australia and Brazil, and is publicly traded on The Toronto
Stock Exchange (symbol: ISD).
IDS's website is located at www.idsdetection.com |
